NANG KUANG (1752) reported revenue of NT$200.2 million for Oct 2026, +6.6% year on year and +23.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.77 billion (-3.3% year on year).
In Oct 2026, it ranked No. 41 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$200.2 million | +6.6% | +23.5% |
| Sep 2026 | NT$162.1 million | -14.4% | -4.2% |
| Aug 2026 | NT$169.2 million | +12.4% | -1.6% |
| Jul 2026 | NT$171.8 million | -6.6% | +10.8% |
| Jun 2026 | NT$155.1 million | -18.1% | -17.0% |
| May 2026 | NT$186.8 million | +7.5% | -5.1% |
| Apr 2026 | NT$196.7 million | +10.2% | +21.6% |
| Mar 2026 | NT$161.8 million | -14.2% | +3.7% |
| Feb 2026 | NT$156 million | -20.0% | -26.4% |
| Jan 2026 | NT$211.8 million | +8.2% | +19.7% |
| Dec 2025 | NT$177 million | -10.6% | +16.2% |
| Nov 2025 | NT$152.4 million | -7.7% | -18.8% |
| Oct 2025 | NT$187.8 million | -13.1% | -0.8% |
| Sep 2025 | NT$189.4 million | +0.3% | +25.8% |
| Aug 2025 | NT$150.6 million | -18.8% | -18.1% |
| Jul 2025 | NT$183.9 million | -10.7% | -2.8% |
| Jun 2025 | NT$189.3 million | +19.1% | +8.9% |
| May 2025 | NT$173.8 million | -9.7% | -2.7% |
| Apr 2025 | NT$178.6 million | +11.0% | -5.3% |
| Mar 2025 | NT$188.6 million | +12.3% | -3.4% |
| Feb 2025 | NT$195.1 million | +42.7% | -0.4% |
| Jan 2025 | NT$195.8 million | -12.5% | -1.1% |
| Dec 2024 | NT$198.1 million | +41.5% | +19.9% |
| Nov 2024 | NT$165.1 million | -6.2% | -23.5% |
| Oct 2024 | NT$216 million | +7.9% | +14.4% |
Jan–Oct 2026 cumulative: NT$1.77 billion (-3.3% YoY)
Other Biotech & Medical companies
Compare with peers: NANG KUANG vs PEC / NANG KUANG vs Lotus Pharm / NANG KUANG vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16